Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens

ISSN Print: 2325-7075
ISSN Online: 2325-7083
www.scirp.net/journal/crcm
E-mail: [email protected]

Citations

"Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens"
written by Olivier Dubreuil, Aziz Zaanan, Olivier Pellerin, Jean-Baptiste Bachet, Philippe Rougier, Julien Taieb,
published by Case Reports in Clinical Medicine, Vol.4 No.4, 2015

has been cited by the following article(s):

[1]	Is there any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer? report of two cases and literature review
	INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 2018

[2]	Is ther e any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer? report of two cases and literatur e review
	2018

[3]	Is there any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer
	2018

[4]	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
	Targeted Oncology, 2017

[5]	Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance
	Journal of the National Comprehensive Cancer Network, 2016